Fig. 3

Cancer-specific survival rates of the groups categorized by expression levels of a ARL4C, b ECT2, c SOD2, and d STEAP3 in a cohort of 36 patients with metastatic RCC. Shorter survival from the time of diagnosis of metastasis is seen in cases with higher expression levels of ARL4C (log-rank test, a p = 0.006, chi-square value = 7.53), SOD2 (log-rank test, c p = 0.011, chi-square value = 6.54), and STEAP3 (log-rank test, d p = 0.003, chi-square value = 8.95). e The patients were divided into high- and low-risk scored groups under our model of risk stratification by setting the cut-off value to 17 points; the high- (> 17) risk score predicted likely demise within 2 years more accurately than each individual biomarker (log-rank test, e p < 0.001, chi-square value = 21.66)